Rho Kinase (ROCK) Inhibitors for the Treatment of Glaucoma
Open Access
- 1 February 2024
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 25 (2) , 94-107
Abstract
Glaucoma is the most common cause of irreversible blindness worldwide. It is characterized by progressive optic nerve degeneration and loss of visual field. Pathological increased intraocular pressure is its main modifiable risk factor. Rho kinase inhibitors are developed as a new class of glaucoma medication that increases outflow facility from the conventional aqueous humor outflow pathway. Additionally, they also have neuroprotective and anti-scarring effects that can might increase the success rate of glaucoma filtration surgery. This review aims to summarize the current concept of Rho kinase inhibitors in the treatment of glaucoma from beach to bedside.Keywords
This publication has 145 references indexed in Scilit:
- Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24 MonthsAdvances in Therapy, 2022
- An in vitro study of scarring formation mediated by human Tenon fibroblasts: Effect of Y‐27632, a Rho kinase inhibitorCell Biochemistry and Function, 2019
- Safety and Efficacy of Ripasudil in Japanese Patients with Glaucoma or Ocular Hypertension: 3-month Interim Analysis of ROCK-J, a Post-Marketing Surveillance StudyAdvances in Therapy, 2019
- RKI-1447, a Rho kinase inhibitor, causes ocular hypotension, actin stress fiber disruption, and increased phagocytosisGraefe's Archive for Clinical and Experimental Ophthalmology, 2018
- Rho signaling research: history, current status and future directionsFEBS Letters, 2018
- Mitomycin C versus 5-Fluorouracil for wound healing in glaucoma surgeryCochrane Database of Systematic Reviews, 2015
- Additive Intraocular Pressure–Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or LatanoprostJAMA Ophthalmology, 2015
- Phase 1 Clinical Trials of a Selective Rho Kinase Inhibitor, K-115JAMA Ophthalmology, 2013
- Effects of endothelin-1 on calcium-independent contraction of bovine trabecular meshworkGraefe's Archive for Clinical and Experimental Ophthalmology, 2008
- RhoA, RhoB, RhoC, Rac1, Cdc42, and Tc10 mRNA levels in spinal cord, sensory ganglia, and corticospinal tract neurons and long‐lasting specific changes following spinal cord injuryJournal of Comparative Neurology, 2005